Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Natera, Inc.

Stage 2 · Advancing · week 20

As of Oct 22, 2026, Natera is in Stage 2, the uptrend phase, now in week 20 (since Jun 4, 2026). It closed at $401.37, 5.7% below its 52-week high and above its 200-day average, which is rising.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. More about the company

$401.37
-2.91% today
$57.9B · Large cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care

Is NTRA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 62w
S2 21w
S2 20w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 1w → S2 7w → S3 2w → S4 6w → S1 3w → S2 62w → S3 12w → S2 9w → S3 2w → S4 5w → S1 1w → S2 21w → S3 13w → S4 2w → S1 1w → S2 20w current
Total tracked: 166 weeks across 16 stage runs.

NTRA among Diagnostics & Research5th of 44 by relative strength

All 44 →
Stocks in Diagnostics & Research ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CDNAStage 2 · wk 2499+27.3%
2BDSXStage 2 · wk 1898−18.3%
3ILMNStage 2 · wk 2497+5.5%
4GHStage 2 · wk 2197−7.6%
5NTRAStage 2 · wk 2096+2.7%
6CRLStage 2 · wk 1692+22.5%
7RVTYStage 2 · wk 1890+10.7%
8PSNLStage 2 · wk 1790−3.2%
vs 52W High
-5.7%
$182.65 lo$425.64 hi
5.7% below 52W high, pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 20
1w13w26w
Week 20, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
53.9%
200 DMA: $260.88 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
1.08x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
Short-term trend rising strongly
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+2.7%
3M
+53.2%
6M
+99.5%
YTD
+75.4%
1Y
+114.8%
Scan Membership
Breakout Watch
Latest: 2025-05-28
10 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 20 · Vol 1.08x
2026-10-21S2
Wk 20 · Vol 0.70x
2026-10-20S2
Wk 20 · Vol 0.65x
2026-10-19S2
Wk 19 · Vol 0.85x
2026-10-16S2
Wk 19 · Vol 1.01x
2026-10-15S2
Wk 19 · Vol 0.77x
2026-10-14S2
Wk 19 · Vol 0.66x
2026-10-13S2
Wk 19 · Vol 0.72x
2026-10-12S2
Wk 18 · Vol 0.59x
2026-10-09S2
Wk 18 · Vol 0.64x
2026-10-08S2
Wk 18 · Vol 1.57x
2026-10-07S2
Wk 18 · Vol 1.85x
Moving averages & range
50 DMA
$365.10
200 DMA
$260.88
52W High
$425.64
52W Low
$182.65
5D Low
$393.44
Resistance levels (recent highs)
20d High
$425.64
60d High
$425.64
120d High
$425.64
250d High
$425.64
Next resistance
+6.0%
to 20d High
ROE
-12.5%
Profit margin -7.1%
Dividend Yield
0.00%
P/B 31.6

Natera: quick answers

What stage is Natera in?

As of Oct 22, 2026, Natera (NTRA) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 4, 2026 and is in week 20. What the four stages mean

Is Natera in an uptrend?

Yes. Natera is in a Stage 2 uptrend. It trades 53.9% above its 200-day average, which is rising.

How far is Natera from its 52-week high?

Natera closed at $401.37 on Oct 22, 2026, 5.7% below its 52-week high of $425.64. Its 52-week low is $182.65.

How has Natera performed over the past year?

As of Oct 22, 2026, Natera is up 114.8% over the past year and up 75.4% so far in 2026.

Which sector and industry is Natera in?

Natera is in the Diagnostics & Research industry, part of the Health Care sector.

About this companyHealth Care· Diagnostics & Research

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.